Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor

Jie Liu; Jun Shiono; Kuniyoshi Shimizu; Akiko Kukita; Toshio Kukita; Ryuichiro Kondo

doi:10.1016/j.bmcl.2009.02.119

Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2154-7. doi: 10.1016/j.bmcl.2009.02.119. Epub 2009 Mar 4.

Authors

Jie Liu¹, Jun Shiono, Kuniyoshi Shimizu, Akiko Kukita, Toshio Kukita, Ryuichiro Kondo

Affiliation

¹ Department of Forest and Forest Products Science, Faculty of Agriculture, Kyushu University, Fukuoka, Japan.

PMID: 19289282
DOI: 10.1016/j.bmcl.2009.02.119

Abstract

Prostate cancer is the most common cancer in men in Western countries, with a high incidence of bone metastasis. Ganoderic acid DM, with 5alpha-reductase inhibitory and androgen receptor (AR) binding activity, isolated from the ethanol extracts of Ganoderma lucidum, can inhibit prostate cancer cell growth and block osteoclastogenesis.

Publication types

Comparative Study

MeSH terms

Androgen Antagonists / chemistry*
Androgen Antagonists / isolation & purification
Androgen Antagonists / pharmacology*
Animals
Antineoplastic Agents / chemistry
Antineoplastic Agents / isolation & purification
Antineoplastic Agents / pharmacology
Cell Differentiation / drug effects*
Cell Line, Tumor
Cell Proliferation / drug effects
Growth Inhibitors / chemistry*
Growth Inhibitors / isolation & purification
Growth Inhibitors / pharmacology
Humans
Male
Mice
Osteoclasts / cytology
Osteoclasts / drug effects*
Osteoclasts / physiology
Rats
Reishi
Triterpenes / chemistry*
Triterpenes / isolation & purification
Triterpenes / pharmacology

Substances

Androgen Antagonists
Antineoplastic Agents
Growth Inhibitors
Triterpenes
ganoderic acid D